Device Trial Radar · NCT06189365
Amplatzer Amulet China Post Market Study (PMS)
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
50
Actual
Start
Jan 30, 2024
Primary completion
Dec 5, 2025
Study completion Dec 5, 2025
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Jan 3, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to prospectively evaluate the safety and effectiveness of the Amplatzer Amulet LAA occluder in a Chinese patient population indicated for use of this device.
Conditions
- Non-Valvular Atrial Fibrillation
Interventions
Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluderDevice
Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Short-Term Safety Endpoint: Occurrence of Major Adverse EventsTime frame: 7 days
- Primary Long-Term Safety Endpoint: Occurrence of Device Embolization, Device Erosion, Significant Device Interference With Surrounding Structure, Device Thrombus, Device Fracture, Device Related Infections, Device Breakage, or Device Related AllergyTime frame: 2 years
- Primary Effectiveness Endpoint: Composite of Ischemic Stroke or Systemic EmbolismTime frame: 2 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, China
Wuhan Asia Heart Hospital
Wuhan, Hubei, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.